Context Therapeutics Inc.

Context Therapeutics is a clinical-stage biopharmaceutical company that advances T cell engaging bispecific antibody therapeutics for the treatment of solid tumors. Its drug development pipeline targets patient populations with unmet oncology needs, including gynecologic, testicular, bladder, lung, colon, and breast cancers. The company's lead investigational drug candidates include CTIM-76, CT-95, and CT-202, which direct immune responses against specific tumor-associated antigens such as Claudin 6, Mesothelin, and Nectin-4. Because Context Therapeutics remains in clinical development, it has not brought commercial products to market.

The company operates without internal manufacturing, sales, or commercial product distribution facilities, choosing to outsource research, drug product manufacturing, and diagnostic preparation to external contract partners. It pursues clinical trials and global patent protection across multiple jurisdictions, including the United States, Europe, Canada, Australia, and parts of Asia, while retaining worldwide development and commercialization rights to its core programs. Context Therapeutics does not identify specific physical headquarters locations or facility counts in the provided text.

Summary of the business section of Context Therapeutics's latest annual report, written by StockData.

“As of March 1, 2026, we had fifteen full-time employees and no part-time employees.”